Allergan's Big Deal: A Buyout, Not A Split, Appeases Wary Investors
Executive Summary
Allergan was expected to announce soon that it would follow its shareholders' advice and split the company in two, but it's being acquired by AbbVie for $63bn instead, finally giving investors a big boost in their Allergan holdings after years of decline.